The table below shows KalVista Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Revenue
$40.86M
$13.70M
$1.40M
-
-
$0.00
Cost of revenue
$3.09M
$1.23M
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$12.42M
$11.99M
$15.16M
$14.17M
$12.59M
$18.68M
SG&A
KALV annual revenue (10-K history)
KalVista Pharmaceuticals, Inc. reported annual revenue of $50.00M for fiscal year 2024. That is up 294.0% from $12.69M in fiscal 2020. Over the 6 fiscal years shown, annual revenue grew from $2.13M (FY 2016) to $50.00M. Figures come from the company's audited annual reports as filed with the SEC.